The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training (TherPsySE)

This trial (n=48) will follow therapists as they embark on their own psychedelic experiences. The trial’s focus is on the benefits and risks to both the therapists and the patients (and their interaction).

Topic Safety

Compound MDMA LSD Psilocybin

Country Switzerland

Visit trial

Status Not yet recruiting

Results Published

Start date 01 December 2022

End date 01 June 2029

Chance of happening 100%

Phase Not Applicable

Design Open

Type Interventional

Generation First

Participants 48

Sex All

Age 27- 99

Therapy No

Trial Details

The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced altered states of consciousness for physicians or psychotherapists in the context of a training course for substance-assisted therapy. Specifically, the study aims to assess changes in therapeutic attitude and other factors important in interactions between patients and therapists (such as empathy and cognitive flexibility).

NCT Number

Sponsors & Collaborators

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.